Testosterone Therapy in Older Men with Late-Onset Hypogonadism: A Counter-Rationale

2013 ◽  
Vol 19 (5) ◽  
pp. 853-863 ◽  
Author(s):  
Shehzad Basaria
Keyword(s):  
Late Onset ◽  
Older Men ◽  
Testosterone Therapy ◽  
Late Onset Hypogonadism

Late-Onset Hypogonadism and Testosterone Replacement in Older Men

2015 ◽  
Vol 31 (4) ◽  
pp. 631-644 ◽  
Author(s):  
Rajib K. Bhattacharya ◽  
Shelley B. Bhattacharya
Keyword(s):  
Late Onset ◽  
Older Men ◽  
Testosterone Replacement ◽  
Late Onset Hypogonadism

scholarly journals Risks of testosterone therapy in elderly men

F1000Research ◽  
2014 ◽  
Vol 3 ◽  
pp. 11 ◽  
Author(s):  
Ranjith Ramasamy ◽  
James M. Dupree ◽  
Jason R. Kovac ◽  
Larry I. Lipshultz
Keyword(s):  
Risk Factor ◽  
Cardiovascular Risk ◽  
Bone Density ◽  
Energy Level ◽  
Independent Risk Factor ◽  
Late Onset ◽  
Elderly Men ◽  
Testosterone Therapy ◽  
Beneficial Effects ◽  
Late Onset Hypogonadism

Testosterone supplementation therapy (TST) is a widely used treatment for men with late onset hypogonadism. The benefits seen with TST, such as improved libido and energy level, beneficial effects on bone density have been well documented. Although hypogonadism remains an independent risk factor for mortality, recent studies have examined the association between testosterone therapy and cardiovascular risk.

scholarly journals Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report

2019 ◽  
Vol 7 ◽  
pp. 2050313X1882345 ◽  
Author(s):  
Ahmad Haider ◽  
Karim Haider ◽  
Farid Saad ◽  
Markolf Hanefeld
Keyword(s):  
Type 2 Diabetes ◽  
Complete Remission ◽  
Late Onset ◽  
Testosterone Deficiency ◽  
Testosterone Therapy ◽  
Urinary Tract Symptoms ◽  
Remission Of Diabetes ◽  
Clinically Significant ◽  
Late Onset Hypogonadism

For obese type 2 diabetes patients, weight reduction is one of the most important measures but fails in most cases. Testosterone deficiency can be the reason for such failure. This case presents a 57-year-old man who was referred to a urologist due to benign prostatic hyperplasia and erectile dysfunction. He had type 2 diabetes, was overweight, and had hypertension and dyslipidemia. The blood test revealed testosterone deficiency. Under testosterone therapy, the patient lost 10 kg; cardiometabolic parameters returned to normal and lower urinary tract symptoms disappeared; complete remission of diabetes was recorded. Overweight and obese patients with type 2 diabetes should be tested for hypogonadism and testosterone therapy, if indicated, be considered. These patients can considerably benefit from testosterone therapy in terms of sustainable weight loss and a clinically significant reduction of cardiometabolic risk factors including complete remission of diabetes.

Sexual dysfunction in the older man

2009 ◽  
Vol 19 (4) ◽  
pp. 237-248 ◽  
Author(s):  
M Albersen ◽  
AW Shindel ◽  
TF Lue
Keyword(s):  
Sexual Dysfunction ◽  
Sexual Behaviour ◽  
Premature Ejaculation ◽  
Late Onset ◽  
Later Life ◽  
Older Men ◽  
Health Issues ◽  
Pharmacological Treatments ◽  
Geriatric Population ◽  
Late Onset Hypogonadism

SummaryAge is strongly associated with risk of sexual dysfunction in both men and women. For many years it was assumed that such a loss of sexuality was natural and inevitable, and therefore little attention was given to sexual behaviour and treatment in this population. However, more recent data have suggested that sexuality remains important into later life for many individuals. Although appreciation of sexuality persists, a decline in sexual activity is typical with advancing age, which is in part attributable to both general health problems and specific sexual dysfunctions, both becoming more prevalent with ageing. The principle sexual health issues in older men include erectile dysfunction and late onset hypogonadism. Although premature ejaculation is prevalent in older men, the bother from this disorder is generally lower in older men. This manuscript consists of a review of the contemporary peer-reviewed literature and attempts to provide insights for the physician treating the geriatric population. We discuss sexual behaviour at older age, and address erectile and androgen biology in older men and the prevalence and aetiology of sexual dysfunction in this population. Furthermore, an overview of contemporary pharmacological treatments for older men's sexual problems is provided.

Influence of Androgen Receptor CAG Polymorphism on Sexual Function Recovery after Testosterone Therapy in Late‐Onset Hypogonadism

2015 ◽  
Vol 12 (2) ◽  
pp. 381-388 ◽  
Author(s):  
Giacomo Tirabassi ◽  
Giovanni Corona ◽  
Andrea Biagioli ◽  
Eddi Buldreghini ◽  
Nicola delli Muti ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Sexual Function ◽  
Late Onset ◽  
Testosterone Therapy ◽  
Function Recovery ◽  
Cag Polymorphism ◽  
Late Onset Hypogonadism

Testosterone Therapy for Late-Onset Hypogonadism Improves Erectile Function: A Systematic Review and Meta-Analysis

2021 ◽  
pp. 1-14
Author(s):  
Hisanori Taniguchi ◽  
Seiji Shimada ◽  
Hidefumi Kinoshita
Keyword(s):  
Systematic Review ◽  
Erectile Function ◽  
Late Onset ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Testosterone Therapy ◽  
Randomized Controlled ◽  
Testosterone Gel ◽  
Function Domain ◽  
Late Onset Hypogonadism

<b><i>Introduction:</i></b> Randomized controlled trials (RCTs) of testosterone therapy (TTh) for late-onset hypogonadism are systematically reviewed and a meta-analysis to assess the efficacy of TTh in improving erectile function is performed. <b><i>Methods:</i></b> The PubMed, Cochrane Library, and Web of Science databases were searched to identify RCTs published from 2007. RCTs that assessed erectile function using the erectile function domain of the International Index of Erectile Function (IIEF-EFD) were included in the meta-analysis. <b><i>Results:</i></b> The systematic review included 18 RCTs and the meta-analysis included 6 studies that enrolled a total of 1,458 patients. The overall meta-analysis revealed that the IIEF-EFD score was significantly improved in the TTh group compared with the placebo group (mean difference 1.86; 95% confidence interval 1.01–2.72; <i>p</i> &#x3c; 0.0001). Compared with patients receiving placebo, there was a significant improvement in the IIEF-EFD of patients who received TTh using testosterone gel, those who received TTh for over 30 weeks, and those without diabetes mellitus or metabolic syndrome. <b><i>Conclusion:</i></b> TTh achieved a significant improvement in the IIEF-EFD score of hypogonadal men compared with placebo, especially in those who received testosterone gel, were treated for over 30 weeks, and had no comorbidities.

Sign in / Sign up

Export Citation Format

Share Document